VisionCare Ophthalmic Technologies Newswire

VisionCare Ophthalmic Technologies Newswire

Comprehensive Real-Time News Feed for VisionCare Ophthalmic Technologies.

Results 1 - 20 of 688 in VisionCare Ophthalmic Technologies

  1. This health-care dividend giant has crushed the S&P 500Read the original story w/Photo

    Tuesday | The Globe and Mail

    John Heinzl is the dividend investor for Globe Investor's Strategy Lab . Follow his contributions here .

    Comment?

  2. Johnson And Johnson: No Time To WaitRead the original story w/Photo

    Monday Jul 25 | Seeking Alpha

    Second Quarter Earnings Beat Expectations. Johnson and Johnson just reported that its adjusted second quarter earnings came in at $1.74 per share, six cents better than the average analyst estimate and three cents better than what it earned a year earlier.

    Comment?

  3. 30+ at Johnson & Johnson's DePuy Subsidiary Will Stand Trial on Fraud-Related ChargesRead the original story

    Sunday Jul 24 | BioSpace

    A total of 30 people are to stand trial on fraud-related charges in connection to the sale of orthopedic equipment to Greek hospitals by a subsidiary of Johnson & Johnson between 2000 and 2006, according to court documents seen by Kathimerini. Executives of the company concerned, DePuy, are alleged to have bribed Greek doctors in order to secure the contracts for the equipment.

    Comment?

  4. Traders Buy Shares of Johnson & Johnson (JNJ) on WeaknessRead the original story w/Photo

    Sunday Jul 24 | Daily Political

    Traders purchased shares of Johnson & Johnson on weakness during trading hours on Friday. $222.43 million flowed into the stock on the tick-up and $114.14 million flowed out of the stock on the tick-down, for a money net flow of $108.29 million into the stock.

    Comment?

  5. Johnson & Johnson: A Dividend King With 54 Years Of Dividend IncreasesRead the original story w/Photo

    Sunday Jul 24 | Seeking Alpha

    Johnson & Johnson is extremely diversified in the medical health field with new drugs leading the way. The company is a defensive business that will make money in a recession.

    Comment?

  6. Better Buy: Intuitive Surgical, Inc. vs. Johnson & JohnsonRead the original story w/Photo

    Friday Jul 22 | The Motley Fool

    In the end, I called it a draw. Since then, Johnson & Johnson has edged Intuitive Surgical out by a hair, with an 11% return versus a 9% return, respectively.

    Comment?

  7. Q3 2016 EPS Estimates for Johnson & Johnson Raised by Leerink SwannRead the original story w/Photo

    Friday Jul 22 | AmericanBankingNews.com

    Analysts at Leerink Swann increased their Q3 2016 EPS estimates for Johnson & Johnson in a research report issued to clients and investors on Wednesday. Leerink Swann analyst D. Antalffy now forecasts that the brokerage will post earnings per share of $1.63 for the quarter, up from their prior estimate of $1.60.

    Comment?

  8. Johnson & Johnson subsidiary to pay $18M in whistle-blower lawsuitRead the original story w/Photo

    Friday Jul 22 | The Jersey Journal

    A California-based subsidiary of Johnson & Johnson will pay $18 million to settle allegations it falsely marketed a sinus surgery device as a means of delivering medication, the U.S. Justice Department announced Friday. Acclarent Inc., the subsidiary, made a balloon-style catheter called the Stratus that was used by surgeons to maintain sinus openings following surgery.

    Comment?

  9. Johnson & Johnson (JNJ) Gets Price Target Hike at Deutsche BankRead the original story w/Photo

    Thursday Jul 21 | TheStreet.com

    The firm maintained its "buy" rating on the New Brunswick, NJ-based pharmaceutical and consumer goods company, citing its diversified portfolio, strong balance sheet, and improvements across all three of its divisions. "J&J is a master of its own destiny with the luxury of time on its size as the business today is strong and outlook bright," Deutsche Bank said in an analyst note.

    Comment?

  10. Johnson & Johnson (JNJ) is Patton Albertson Miller Group LLC's 10th Largest PositionRead the original story w/Photo

    Wednesday Jul 20 | Daily Political

    Patton Albertson Miller Group LLC reduced its stake in Johnson & Johnson by 1.7% during the first quarter, Holdings Channel reports. The firm owned 32,237 shares of the company's stock after selling 551 shares during the period.

    Comment?

  11. Here's My Top Stock to Buy in JulyRead the original story w/Photo

    Wednesday Jul 20 | The Motley Fool

    The world will turn its attention to Brazil next month as it hosts the Olympics. Bargain-hunting investors may want to do the same.

    Comment?

  12. Johnson & Johnson (JNJ) Stock Rating Reaffirmed by RBC Capital MarketsRead the original story w/Photo

    Wednesday Jul 20 | AmericanBankingNews.com

    's stock had its "outperform" rating restated by investment analysts at RBC Capital Markets in a research note issued on Wednesday. They currently have a $133.00 price target on the stock, up from their previous price target of $125.00.

    Comment?

  13. Leerink Swann Reiterates "Outperform" Rating for Johnson & JohnsonRead the original story w/Photo

    Wednesday Jul 20 | AmericanBankingNews.com

    's stock had its "outperform" rating restated by equities researchers at Leerink Swann in a report issued on Wednesday. They currently have a $140.00 price objective on the stock, up from their prior price objective of $125.00.

    Comment?

  14. 3 Compelling Reasons to Buy Johnson & Johnson Following EarningsRead the original story w/Photo

    Wednesday Jul 20 | TheStreet.com

    This health and drug giant is the best in its class. Here is why investors need to load up on J&J stock, which won't disappoint over the long run.

    Comment?

  15. Johnson & Johnson (JNJ) PT Raised to $145.00Read the original story w/Photo

    Wednesday Jul 20 | AmericanBankingNews.com

    The firm currently has a "buy" rating on the stock. Argus' price target indicates a potential upside of 15.77% from the stock's previous close.

    Comment?

  16. Global stocks resilient amid solid corporate earningsRead the original story w/Photo

    Wednesday Jul 20 | Valley Morning Star

    Stock markets around the world were proving resilient on Wednesday in the face of a fairly gloomy economic outlook from the International Monetary Fund.

    Comment?

  17. Dow inches to record highRead the original story w/Photo

    Tuesday Jul 19 | Albany Times Union

    In this July 30, 2013, file photo, large banners hang in an atrium at the headquarters of Johnson & Johnson in New Brunswick, N.J. Johnson & Johnson reports financial results on Tuesday, July 19, 2016. ORG XMIT: NYBZ203 less FILE - In this July 30, 2013, file photo, large banners hang in an atrium at the headquarters of Johnson & Johnson in New Brunswick, N.J. Johnson & Johnson reports financial results on Tuesday, July 19, 2016.

    Comment?

  18. Johnson & Johnson (JNJ) Shares Bought by Washington Trust CoRead the original story w/Photo

    Tuesday Jul 19 | Daily Political

    WASHINGTON TRUST Co increased its stake in Johnson & Johnson by 3.7% during the first quarter, Holdings Channel reports. The fund owned 110,919 shares of the company's stock after buying an additional 3,967 shares during the period.

    Comment?

  19. Dow notches eights day of gains; Microsoft beatsRead the original story w/Photo

    Tuesday Jul 19 | Reuters

    The S&P 500 pulled back from record highs, while the Dow edged up for an eighth straight day of gains. Bobbi Rebell reports.

    Comment?

  20. While you were sleeping: IMF downgrades, Netflix dropsRead the original story w/Photo

    Tuesday Jul 19 | NBR Newsroom

    Wall Street moved lower as disappointing earnings from Netflix, among others, and the International Monetary Fund's downgrade of its outlook for the global economy weighed on sentiment. The IMF cut its forecasts for global economic growth this year and next as the unexpected UK vote to leave the European Union creates a wave of uncertainty amid already-fragile business and consumer confidence, it said in a statement.

    Comment?